JP6684915B2 - 引湿性が改善されたカルベジロール速放性製剤{Carvedilol immediate release formulation having improved madescent} - Google Patents
引湿性が改善されたカルベジロール速放性製剤{Carvedilol immediate release formulation having improved madescent} Download PDFInfo
- Publication number
- JP6684915B2 JP6684915B2 JP2018540450A JP2018540450A JP6684915B2 JP 6684915 B2 JP6684915 B2 JP 6684915B2 JP 2018540450 A JP2018540450 A JP 2018540450A JP 2018540450 A JP2018540450 A JP 2018540450A JP 6684915 B2 JP6684915 B2 JP 6684915B2
- Authority
- JP
- Japan
- Prior art keywords
- carvedilol
- polyvinyl alcohol
- coating layer
- fatty acid
- preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
- A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/282—Organic compounds, e.g. fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/288—Compounds of unknown constitution, e.g. material from plants or animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Botany (AREA)
- Zoology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Oil, Petroleum & Natural Gas (AREA)
Description
を含む。本発明において、薬剤学的に許容される塩は、患者に対して比較的非毒性でかつ無害な濃度で使用され、この塩の有する副作用が薬効成分の有益な効果を低下させない任意の有機または無機付加塩を示す。
た積層体も適用することができる。
下記表1のような組成により、カルベジロール、粉砕白糖、マンニトール、乳糖水和物、クロスポビドンおよび軽質無水ケイ酸を混合した後、ポビドンを精製水に溶解させて得たポビドン液によって顆粒化した。顆粒化産物を乾燥および整粒した後、クロスポビドン
、軽質無水ケイ酸およびステアリン酸マグネシウムと混合した後に打錠(圧縮)して比較例1〜3の裸錠を製造した。比較例3の裸錠は、さらにヒドロキシプロピルメチルセルロース、酸化チタンおよびポリエチレングリコール400を下記表1の量で含むコーティング分散液でコーティングしてコーティング錠を製造した。
実施例1〜8のコーティング錠は、比較例1と2の裸錠を、下記の表2に示した成分を含むコーティング分散液で、フィルムコーティング率(%)に対応する量でコーティングすることによって製剤した。
実施例1〜8のコーティング錠、比較例1〜2の裸錠および比較例3のコーティング錠を「大韓薬典」の一般試験法中の溶出試験法第2法に従って毎分90回転で溶出試験を行った。試験開始から30分後、紫外吸光光度計を用いて285nm波長でカルベジロールの放出率を算出した。その結果を下記表3に示した。試験液は、pH4.5クエン酸緩衝液1000mLである。
下記の保管条件に応じて包装されていない実施例1〜8のコーティング錠、比較例1〜2の裸錠および比較例3のコーティング錠を保管し、その外観を確認した。
*保管条件:加速保管条件(40±2℃/相対湿度75±5%)
Claims (5)
- カルベジロールを有効成分として含む速放性製剤であって、前記製剤は表面に形成されたコーティング層を含み、前記コーティング層はポリビニルアルコールおよびグリセリン脂肪酸エステル、ポリビニルアルコールおよびプロピレングリコール脂肪酸エステル、ポリビニルアルコールおよびポリビニルアルコール−ポリエチレングリコール共重合体、ポリビニルアルコールおよびメタクリル酸−エチルアクリレート共重合体、ヒドロキシプロピルメチルセルロースおよび脂肪酸、またはヒドロキシプロピルメチルセルロースおよびワックスを含む製剤。
- 前記コーティング層は、前記製剤の全体重量に対して1〜10質量%の重量で用いられている、請求項1に記載の製剤。
- 希釈剤、崩壊剤、結合剤および滑沢剤からなる群より選択される少なくとも1つの添加剤を含む、請求項1に記載の製剤。
- pH4.5クエン酸緩衝液において30分以内にカルベジロールが65%以上放出される、請求項1に記載の製剤。
- 引湿性を防止する請求項1〜4のいずれか1つに記載の製剤。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR10-2016-0015177 | 2016-02-05 | ||
KR1020160015177A KR102158339B1 (ko) | 2016-02-05 | 2016-02-05 | 인습성이 개선된 카르베딜롤 속방성 제제 |
PCT/KR2017/000811 WO2017135627A1 (en) | 2016-02-05 | 2017-01-24 | Carvedilol immediate release formulation having improved madescent |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2019504095A JP2019504095A (ja) | 2019-02-14 |
JP6684915B2 true JP6684915B2 (ja) | 2020-04-22 |
Family
ID=59499686
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2018540450A Active JP6684915B2 (ja) | 2016-02-05 | 2017-01-24 | 引湿性が改善されたカルベジロール速放性製剤{Carvedilol immediate release formulation having improved madescent} |
Country Status (6)
Country | Link |
---|---|
US (1) | US20190038564A1 (ja) |
EP (1) | EP3411020A4 (ja) |
JP (1) | JP6684915B2 (ja) |
KR (1) | KR102158339B1 (ja) |
CN (1) | CN108601742A (ja) |
WO (1) | WO2017135627A1 (ja) |
Family Cites Families (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE19637082A1 (de) * | 1996-09-12 | 1998-03-19 | Boehringer Mannheim Gmbh | Schnellzerfallende Pellets |
BR9814127A (pt) * | 1997-11-12 | 2000-10-03 | Boehringer Mannheim Pharm Corp | Nova forma de dosagem oral para carvedilol |
JP3947654B2 (ja) | 1998-04-09 | 2007-07-25 | ロシュ ダイアグノスティックス ゲーエムベーハー | カルベジロール製剤 |
US6448323B1 (en) * | 1999-07-09 | 2002-09-10 | Bpsi Holdings, Inc. | Film coatings and film coating compositions based on polyvinyl alcohol |
US20010036959A1 (en) | 2000-04-03 | 2001-11-01 | Gabel Rolf Dieter | Carvedilol-hydrophilic solutions |
IN191028B (ja) | 2001-05-17 | 2003-09-13 | Sun Pharmaceutical Ind Ltd | |
WO2004096182A1 (en) | 2003-04-30 | 2004-11-11 | Ranbaxy Laboratories Limited | Extended release matrix tablets of carvedilol |
US20050175695A1 (en) | 2003-11-25 | 2005-08-11 | Catherine Castan | Carvedilol free base, salts, anhydrous forms or solvates thereof, corresponding pharmaceutical compositions, controlled release formulations, and treatment or delivery methods |
US20050169994A1 (en) * | 2003-11-25 | 2005-08-04 | Burke Matthew D. | Carvedilol free base, salts, anhydrous forms or solvates thereof, corresponding pharmaceutical compositions, controlled release formulations, and treatment or delivery methods |
DE102004031835A1 (de) * | 2004-06-30 | 2006-01-19 | Basf Ag | Schnelldispergierbares, feinteiliges, nicht zur Entmischung neigendes pulverförmiges Filmüberzugsmittel basierend auf Polyvinylalkohol-Polyether-Pfropfcopolymeren gekennzeichnet durch besondere physikalische Stabilität und niedrige Rauhigkeit |
EP1811975A2 (en) * | 2004-10-19 | 2007-08-01 | The State of Oregon Acting by and | Enteric coated compositions that release active ingredient(s) in gastric fluid and intestinal fluid |
US20080292695A1 (en) * | 2006-12-01 | 2008-11-27 | Kristin Arnold | Carvedilol forms, compositions, and methods of preparation thereof |
US8574625B2 (en) * | 2007-05-30 | 2013-11-05 | Wockhardt Ltd. | Tablet dosage form |
EP2259801B1 (en) * | 2008-03-04 | 2012-01-04 | Lupin Limited | Stable pharmaceutical compositions of carvedilol |
CA2759985A1 (en) * | 2009-05-12 | 2010-11-18 | Bpsi Holdings, Llc | Enhanced moisture barrier immediate release film coating systems and substrates coated therewith |
US20110229564A1 (en) * | 2010-03-22 | 2011-09-22 | Amneal Pharmaceuticals, L.L.C. | Pharmaceutical Compositions Of Carvedilol Salts And Process For Preparation Thereof |
KR102241487B1 (ko) | 2013-02-20 | 2021-04-16 | 주식회사 종근당 | 제어방출 펠릿으로 된 약제학적 조성물 |
AU2015209674B2 (en) * | 2014-01-21 | 2018-11-08 | Bpsi Holdings, Llc | Immediate release film coatings containing medium chain glycerides and substrates coated therewith |
-
2016
- 2016-02-05 KR KR1020160015177A patent/KR102158339B1/ko active IP Right Grant
-
2017
- 2017-01-24 WO PCT/KR2017/000811 patent/WO2017135627A1/en active Application Filing
- 2017-01-24 CN CN201780010145.1A patent/CN108601742A/zh active Pending
- 2017-01-24 US US16/075,399 patent/US20190038564A1/en not_active Abandoned
- 2017-01-24 EP EP17747672.8A patent/EP3411020A4/en not_active Withdrawn
- 2017-01-24 JP JP2018540450A patent/JP6684915B2/ja active Active
Also Published As
Publication number | Publication date |
---|---|
KR102158339B1 (ko) | 2020-09-21 |
US20190038564A1 (en) | 2019-02-07 |
CN108601742A (zh) | 2018-09-28 |
WO2017135627A1 (en) | 2017-08-10 |
JP2019504095A (ja) | 2019-02-14 |
KR20170093589A (ko) | 2017-08-16 |
EP3411020A1 (en) | 2018-12-12 |
EP3411020A4 (en) | 2019-10-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP4795955B2 (ja) | 複数の被覆層を有するフィルムコーティング錠 | |
JP2011098964A5 (ja) | ||
US20120301541A1 (en) | Compressed core for pharmaceutical composition | |
HU226580B1 (en) | Pharmaceutical formulation comprising a 2-[[(2-pyridinyl)methyl]sulfinyl] benzimidazole having anti-ulcer activity and a process for the preparation of such formulation | |
US20130243859A1 (en) | Orally disintegrating tablet | |
US9629808B2 (en) | Sustained-release solid preparation for oral use | |
PT2468361E (pt) | Formulações de vildagliptina | |
WO2015145462A1 (en) | Pharmaceutical compositions of dabigatran | |
US20150366807A1 (en) | Oral pharmaceutical composition comprising dabigatran etexilate | |
TWI739756B (zh) | 一種含有喹啉衍生物或其鹽的醫藥組成物 | |
EP2641594B1 (en) | Enteric coated solid pharmaceutical compositions for proton pump inhibitors | |
TWI592154B (zh) | Allisartan-based solid dispersions and pharmaceutical compositions containing the solid dispersions | |
WO2014060561A1 (en) | Oral pharmaceutical formulations comprising dabigatran | |
TWI658841B (zh) | 包含苯并咪唑衍生物的新穎調配物 | |
US20190240158A1 (en) | Immediate release tablet of dofetilide | |
JP4874797B2 (ja) | フィルムコーティング錠 | |
JP6684915B2 (ja) | 引湿性が改善されたカルベジロール速放性製剤{Carvedilol immediate release formulation having improved madescent} | |
KR20080096779A (ko) | 신규 필름 코팅정 | |
WO2010120963A1 (en) | Tablet formulation for p38 inhibitor and method | |
JP6824549B2 (ja) | 経口固形製剤およびその製造法 | |
US10016417B2 (en) | Extended release formulation of a direct thrombin inhibitor | |
JP2018184382A (ja) | エゼチミブ含有錠剤およびその製法 | |
JP2013536832A (ja) | ミルナシプランの制御放出医薬組成物 | |
JP2003231637A (ja) | 固形製剤 | |
JP2019014712A (ja) | 安定なダビガトラン製剤 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20181002 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20190628 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20190710 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20191008 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20191023 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20200311 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20200330 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6684915 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |